Hormonal dysregulation and bones in thalassaemia--an overview
- PMID: 19337163
Hormonal dysregulation and bones in thalassaemia--an overview
Abstract
Bone disease (BDT) represents a prominent cause of morbidity in patients of both sexes with thalassaemia major (TM). The exact pathogenesis of BDT in TM is multifactorial, still unclear and complicated. Peak bone mass is achieved shortly after completion of puberty and normally remains stable until the third decade of life. After the age of 30 years, age related bone loss begins. Growth hormone (GH) and sex steroids have a crucial role in bone remodelling and therefore are important in helping to establish and maintain peak bone mass for both sexes. The anabolic effects of GH and IGF-1 in bone are important not only for the acquisition of bone mass during adolescence but also for the maintenance of skeletal architecture during adult life. GH deficiency is not a rare finding in adult patients with TM, thus contributing to the development of BDT. Furthermore, patients with TM are often hypogonadal, and therefore the lack of sex steroids in critical periods, such as puberty, contributes to the failure to achieve optimal peak bone mass and to maintain bone mass later in life. Sex steroids probably act by increasing the expression of RANKL by osteoblastic cells, and alterations in the RANK/RANKL/OPG system in favour of osteoclasts are characteristic in TM, where the ratio of sRANKL/OPG is increased. It is still not clear whether DEXA scan is the gold standard for determination of bone density in thalassaemics and if so, whether the WHO criteria for defining osteopenia and osteoporosis are relevant to patients with TM. The question therefore arises whether other methods should be adopted, since DEXA may often overestimate BDT in these patients. BDT in thalassaemia represents a unique clinical entity with a multifactorial aetiology and of complex mechanisms which need to be clarified. It is essential for us to understand the underlying mechanisms of bone destruction and the bony defect at the ultrastructural level in order to be able to design not only preventive strategies but also therapeutic measures.
Similar articles
-
Osteoporosis syndrome in thalassaemia major: an overview.J Osteoporos. 2010 May 26;2010:537673. doi: 10.4061/2010/537673. J Osteoporos. 2010. PMID: 20976089 Free PMC article.
-
Bone disease in thalassaemia major: recent advances in pathogenesis and clinical aspects.Pediatr Endocrinol Rev. 2011 Mar;8 Suppl 2:300-6. Pediatr Endocrinol Rev. 2011. PMID: 21705982 Review.
-
Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major.Panminerva Med. 2009 Mar;51(1):17-23. Panminerva Med. 2009. PMID: 19352306
-
Gender differences in the prevalence and severity of bone disease in thalassaemia.Pediatr Endocrinol Rev. 2008 Oct;6 Suppl 1:116-22. Pediatr Endocrinol Rev. 2008. PMID: 19337164
-
New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia.Br J Haematol. 2004 Oct;127(2):127-39. doi: 10.1111/j.1365-2141.2004.05143.x. Br J Haematol. 2004. PMID: 15461618 Review.
Cited by
-
Osteoporosis syndrome in thalassaemia major: an overview.J Osteoporos. 2010 May 26;2010:537673. doi: 10.4061/2010/537673. J Osteoporos. 2010. PMID: 20976089 Free PMC article.
-
An international registry of survivors with Hb Bart's hydrops fetalis syndrome.Blood. 2017 Mar 9;129(10):1251-1259. doi: 10.1182/blood-2016-08-697110. Epub 2017 Jan 5. Blood. 2017. PMID: 28057638 Free PMC article. Review.
-
Bone and Joint Involvement in Beta Thalassemic Patients: A Cross-sectional Study.Indian J Orthop. 2024 Nov 5;59(1):69-76. doi: 10.1007/s43465-024-01225-0. eCollection 2025 Jan. Indian J Orthop. 2024. PMID: 39735876
-
Bone density in transfusion dependent thalassemia patients in Urmia, Iran.Iran J Ped Hematol Oncol. 2014;4(2):68-71. Epub 2014 Apr 20. Iran J Ped Hematol Oncol. 2014. PMID: 25002928 Free PMC article.
-
Decreased Bone Formation Explains Osteoporosis in a Genetic Mouse Model of Hemochromatosiss.PLoS One. 2016 Feb 1;11(2):e0148292. doi: 10.1371/journal.pone.0148292. eCollection 2016. PLoS One. 2016. PMID: 26829642 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous